Search our Database of Scientific Publications and Authors

I’m looking for a
    Ghost cell glaucoma after intravitreal bevacizumab for postoperative vitreous hemorrhage following vitrectomy for proliferative diabetic retinopathy.
    Ophthalmic Surg Lasers Imaging 2010 Jan-Feb;41(1):72-7
    Department of Ophthalmology, Chang Gung Memorial Hospital, No. 5, Fu-Shin Street, Kweishan, Taoyuan, 333, Taiwan.
    Background And Objective: To report the occurrence of ghost cell glaucoma after intravitreal injection of bevacizumab for the treatment of postoperative vitreous hemorrhage after vitrectomy for proliferative diabetic retinopathy (PDR).

    Patients And Methods: Retrospective chart review from August 2006 to December 2007. Patients who had postoperative vitreous hemorrhage after vitrectomy for PDR and received an intravitreal injection of bevacizumab were enrolled in the study.

    Results: Eight eyes of 8 patients (mean age: 46 years) were included. After intravitreal injection of bevacizumab, 4 (50%) eyes had clearance of vitreous hemorrhage. Three eyes developed ghost cell glaucoma within 1 week after intravitreal injection of bevacizumab. Of these, intraocular pressure was controlled in 1 eye through the use of anti-glaucoma medication, whereas the other 2 eyes needed surgical intervention to lower intraocular pressure and subsequently clear the vitreous hemorrhage.

    Conclusion: Intravitreal injection of bevacizumab may accelerate the clearance of postoperative vitreous hemorrhage in cases of PDR. However, a high incidence of ghost cell glaucoma was observed. Caution should be exercised when administering an intravitreal injection of bevacizumab for a postoperative vitreous hemorrhage after vitrectomy for PDR.

    Similar Publications

    Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy.
    Cochrane Database Syst Rev 2015 Aug 7(8):CD008214. Epub 2015 Aug 7.
    Sunderland Eye Infirmary, Queen Alexandra Road, Sunderland, UK, SR2 9HP.
    Background: Postoperative vitreous cavity haemorrhage (POVCH) is a significant complication following vitrectomy for proliferative diabetic retinopathy (PDR). It delays visual recovery and can make further treatment difficult if the view of the fundus is significantly obscured. A number of interventions to reduce the incidence of POVCH have been proposed, including the perioperative use of anti-vascular endothelial growth factor (anti-VEGF). Read More
    Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial.
    Ophthalmology 2009 Oct 21;116(10):1943-8. Epub 2009 Aug 21.
    Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
    Objective: To evaluate the effect of preoperative intravitreal bevacizumab (IVB) injection on the rate of early (< or =4 weeks) postvitrectomy hemorrhage in patients with proliferative diabetic retinopathy (PDR).

    Design: Prospective, randomized, double-masked clinical trial.

    Participants: Sixty-eight eyes of 68 patients undergoing pars plana vitrectomy for management of PDR complications. Read More
    Role of intravitreal bevacizumab (Avastin) injected at the end of diabetic vitrectomy in preventing postoperative recurrent vitreous hemorrhage.
    Retina 2010 Nov-Dec;30(10):1646-50
    Division of Vitreoretinal Surgery, Dhahran Eye Specialist Hospital, Dhahran, Saudi Arabia.
    Purpose: The purpose of this study was to evaluate the role of bevacizumab (Avastin), an antivascular endothelial growth factor agent, injected at the end of surgery for preventing postoperative recurrent vitreous hemorrhage in patients undergoing vitrectomy for diabetic eye disease.

    Methods: This was a retrospective, comparative, and nonrandomized study on a consecutive series of patients who underwent vitrectomy for diabetic eye disease. Recurrence of postoperative vitreous hemorrhage was compared in patients with and without intravitreal 1. Read More
    Early vitreous hemorrhage after vitrectomy with preoperative intravitreal bevacizumab for proliferative diabetic retinopathy.
    Middle East Afr J Ophthalmol 2013 Jan-Mar;20(1):51-5
    Osaka Rosai Hospital, Clinical Research Center for Occupational Sensory Organ Disability, Kita-Ku, Sakai, Japan.
    Purpose: To evaluate the effect of preoperative intravitreal bevacizumab (IVB) on surgical procedures, visual prognosis, and postoperative complications, especially postoperative vitreous hemorrhage, in cases with proliferative diabetic retinopathy (PDR).

    Materials And Methods: Seventy-one eyes of 54 consecutive patients (23 eyes of 18 women, 48 eyes of 36 men) were investigated in this study. Twenty-five eyes received IVB one to 30 days before the vitrectomy (Bevacizumab Group) and the other 46 eyes had the vitrectomy alone (Control Group). Read More